Evaluation of the Efficacy and Safety of ADL5945 Once Daily for the Treatment of Opioid-induced Constipation in Adults Taking Opioid Therapy for Chronic Noncancer Pain

NCT01275755 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
81
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)